China’s 10 Ministries Issue 15th Five-Year Plan for Pharma, Targeting 20%+ Annual Growth in Innovative Drugs

This is a state-directed industrial policy signal rather than a market event, and its weight comes from the breadth of coordination — ten ministries aligning behind a single sector roadmap. For companies in China's biopharma supply chain, from contract research to API manufacturing, the plan implies sustained policy tailwinds and easier access to state-backed R&D funding, while foreign firms weighing China exposure face a more explicitly domestic-priority framework. The open question is implementation: whether provincial incentives and approval pathways follow the central language, and whether the growth target is met through genuine innovation or capacity expansion.